Your browser doesn't support javascript.
loading
Epilepsy, amyloid-ß, and D1 dopamine receptors: a possible pathogenetic link?
Costa, Cinzia; Parnetti, Lucilla; D'Amelio, Marcello; Tozzi, Alessandro; Tantucci, Michela; Romigi, Andrea; Siliquini, Sabrina; Cavallucci, Virve; Di Filippo, Massimiliano; Mazzocchetti, Petra; Liguori, Claudio; Nobili, Annalisa; Eusebi, Paolo; Mercuri, Nicola B; Calabresi, Paolo.
Afiliación
  • Costa C; Clinica Neurologica, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy. Electronic address: cinzia.costa@unipg.it.
  • Parnetti L; Clinica Neurologica, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.
  • D'Amelio M; Laboratory of Molecular Neuroscience, Department of Medicine, Campus Bio-Medico University, Rome, Italy; Department of Experimental Neurosciences, "Istituto di Ricovero e Cura a Carattere Scientifico", IRCCS Santa Lucia Foundation, Rome, Italy.
  • Tozzi A; Department of Experimental Neurosciences, "Istituto di Ricovero e Cura a Carattere Scientifico", IRCCS Santa Lucia Foundation, Rome, Italy; Department of Experimental Medicine, University of Perugia, Perugia, Italy.
  • Tantucci M; Clinica Neurologica, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.
  • Romigi A; Neurophysiopathology Unit, Department of Systems Medicine, Sleep and Epilepsy Medicine Centre, Tor Vergata University and Hospital, Rome, Italy.
  • Siliquini S; Clinica Neurologica, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.
  • Cavallucci V; Department of Experimental Neurosciences, "Istituto di Ricovero e Cura a Carattere Scientifico", IRCCS Santa Lucia Foundation, Rome, Italy.
  • Di Filippo M; Clinica Neurologica, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.
  • Mazzocchetti P; Clinica Neurologica, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.
  • Liguori C; Department of Experimental Neurosciences, "Istituto di Ricovero e Cura a Carattere Scientifico", IRCCS Santa Lucia Foundation, Rome, Italy.
  • Nobili A; Laboratory of Molecular Neuroscience, Department of Medicine, Campus Bio-Medico University, Rome, Italy; Department of Experimental Neurosciences, "Istituto di Ricovero e Cura a Carattere Scientifico", IRCCS Santa Lucia Foundation, Rome, Italy.
  • Eusebi P; Clinica Neurologica, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.
  • Mercuri NB; Department of Experimental Neurosciences, "Istituto di Ricovero e Cura a Carattere Scientifico", IRCCS Santa Lucia Foundation, Rome, Italy; Neurophysiopathology Unit, Department of Systems Medicine, Sleep and Epilepsy Medicine Centre, Tor Vergata University and Hospital, Rome, Italy.
  • Calabresi P; Clinica Neurologica, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy; Department of Experimental Neurosciences, "Istituto di Ricovero e Cura a Carattere Scientifico", IRCCS Santa Lucia Foundation, Rome, Italy.
Neurobiol Aging ; 48: 161-171, 2016 12.
Article en En | MEDLINE | ID: mdl-27701029
ABSTRACT
Experimental and clinical observations indicate that amyloid-ß1-42 (Aß1-42) peptide not only represents a major actor in neurodegenerative mechanisms but also induce hyperexcitation in individual neurons and neural circuits. In this abnormal excitability, possibly leading to seizures, the D1 dopamine (DA) receptors may play a role. Cerebrospinal fluid levels of Aß1-42 were measured in patients with late-onset epilepsy of unknown etiology. Moreover, the effect of amyloid peptide on the hippocampal epileptic threshold and synaptic plasticity and its link to D1 receptor function were tested in experimental mouse model of cerebral amyloidosis and in acute model of Aß1-42-induced neurotoxicity. Among 272 evaluated epileptic patients, aged >55 years, 35 suffered from late-onset epilepsy of unknown etiology. In these subjects, cerebrospinal fluid Aß1-42 levels were measured. The effects of Aß1-42, amyloid oligomers, and D1 receptor modulation on epileptic threshold were analyzed by electrophysiological recordings in the dentate gyrus of mice hippocampal slices. We found that Aß1-42 levels were significantly decreased in cerebrospinal fluid of patients with late-onset epilepsy of unknown etiology with respect to controls suggesting the cerebral deposition of this peptide in these patients. Aß1-42 enhanced epileptic activity in mice through a mechanism involving increased surface expression of D1 receptor, and this effect was mimicked by D1 receptor stimulation and blocked by SCH 23390, a D1 receptor antagonist. Aß1-42 may contribute to the pathophysiology of late-onset epilepsy of unknown origin. Our preclinical findings indicate that the D1 receptor is involved in mediating the epileptic effects of Aß1-42. This novel link between Aß1-42 and D1 receptor signaling might represent a potential therapeutic target.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fragmentos de Péptidos / Péptidos beta-Amiloides / Receptores de Dopamina D1 / Epilepsia Tipo de estudio: Etiology_studies / Prognostic_studies Idioma: En Revista: Neurobiol Aging Año: 2016 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fragmentos de Péptidos / Péptidos beta-Amiloides / Receptores de Dopamina D1 / Epilepsia Tipo de estudio: Etiology_studies / Prognostic_studies Idioma: En Revista: Neurobiol Aging Año: 2016 Tipo del documento: Article